Introduction:

Current methods are unable to detect cancer therapy resistance in real-time, causing cancer more lethal. Our product detects cancer therapy resistance in Real-time and is Sensitive, Simple, Cost-saving. Our product can also guide optimal drug dose in real-time to reduce side-effects.

The Problems:

1. Ecosystem:

30 - 70% treated drugs become ineffective for the cancer patients due to therapy resistance. Therapy Monitoring detects the resistance & guides Therapy Decision Making. The market is very big.

2. Problems & Current Solution:

Cancer therapy resistances are often detected too late by current methods. This causes disease more complex, patient death, and huge Medicare & economic expenses.

Solutions:

CSE1L is expressed in most cancer types. CSE1L exists in cancer blood

p-CSE1L phosphorylation is regulated by ERK.

Core Technology:

• Signal transduction reaction take time only < 1h.

• Sensitive, Simple, Real-time, & Cost-saving.

• Only we have anti-p-CSE1L antibody.

• CSE1L is expressed in most cancer types, and is correlated with tumor stage & size.

Conclusion:

Our product detects cancer therapy resistance in Real-time and is Sensitive, Simple, Cost- saving. It can also guide optimal drug dose in real-time to reduce side-effects. The product helps patients get the correct drug in time. It prevent patients from spending huge money and time in taking ineffective drugs to lose the golden period of cancer treatment. The product improves precision medicine, reducing the costs and expenditures of family, governments, and Medicare system. The product can be used in hospitals worldwide, promoting the economic growth and biomedical reputation of our country.